NEW YORK, November 5, 2025 — Leads & Copy — Royalty Pharma plc (Nasdaq: RPRX) reported strong third-quarter results for 2025, with Portfolio Receipts growing 11% to $814 million and Royalty Receipts also up 11%. Net cash from operating activities was $703 million. The company raised its full-year 2025 guidance, expecting Portfolio Receipts of $3.2 billion to $3.25 billion.
According to Pablo Legorreta, Royalty Pharma’s founder and CEO, the company is on track for another year of double-digit top-line growth. Royalty Pharma expanded its portfolio with three innovative therapies and increased capital deployment to $2.0 billion for the year. The Investor Day highlighted the rapid growth in the royalty market and the company’s competitive advantages.
Recent capital deployment included acquiring a royalty on Amgen’s Imdelltra for up to $950 million, a funding agreement on obexelimab with Zenas BioPharma for up to $300 million, and a royalty on Alnylam’s Amvuttra for $310 million. The company repurchased four million Class A ordinary shares for $152 million in the third quarter, with total share repurchases reaching $1.2 billion in the first nine months of 2025.
Positive clinical and regulatory updates include Revolution Medicines’ daraxonrasib, which showed positive initial data in first-line metastatic pancreatic cancer, and Roche’s trontinemab, which initiated Phase 3 for Alzheimer’s disease.
The Deloitte report on the biopharma royalty market highlighted royalties’ vital role in fueling the biopharma ecosystem, supporting innovation and commercial success with flexible, non-dilutive capital.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
Source: Royalty Pharma plc
